Blue Jet Healthcare shares experienced a dramatic turnaround, rising nearly 10% to an intraday high of ₹485.15 after the company's March quarter results exceeded Street expectations. According to latest market reports, the stock turned positive after remaining down over 2% post the results release. Despite reporting a double-digit fall in both top line and bottom line for the reporting quarter, the results were above the Street's expectations, with the company demonstrating resilience in challenging market conditions.
Blue Jet Healthcare shares are drawing market attention following disappointing fourth-quarter results that fell short of analyst expectations. According to reports from ET Now, the company's profit declined by 42% during the quarter, marking a significant deterioration in financial performance. The substantial profit decline has raised concerns among investors and analysts about the company's operational efficiency and market positioning. However, the latest market reaction suggests investors are focusing on the company's ability to exceed analyst expectations despite the challenging quarterly performance.
The stock demonstrated exceptional trading activity with around 3 million shares changing hands on NSE, which is over 22 times higher than the number of shares traded till the same time Friday. For a brief period, the stock was the top gainer among the Nifty 500 constituents, highlighting strong investor interest in the company's performance. At 1312 IST, shares of Blue Jet Healthcare traded nearly 8% higher at ₹474.35, reflecting the positive market sentiment following the results announcement.
Despite a 22% increase in Q4 revenue on a quarter-over-quarter basis driven by strong performance in the Contrast Media segment, Blue Jet Healthcare faced significant headwinds throughout FY26. The company's overall revenue declined by 8% compared to FY25, indicating challenges across multiple business segments. The PI/API category saw a significant decline of 35% in revenue for FY26, primarily due to customer destocking, while the artificial sweeteners segment faced pricing pressure from imports, leading to a 2% decline compared to FY25.
Looking ahead, Blue Jet Healthcare has commenced its Vizag greenfield expansion project, which is expected to be a significant long-term growth platform. The company is preparing for future expansion in its Contrast Media segment, which is showing promising growth prospects. However, logistics costs are expected to increase in FY27, which could impact overall profitability, highlighting the need for careful cost management as the company navigates its expansion phase.
